Projecting future drug expenditures--2010.

PURPOSE Drug expenditure trends in 2008 and 2009, projected drug expenditures for 2010, and factors likely to influence drug expenditures are discussed. SUMMARY Various factors are likely to influence drug expenditures in 2010, including drugs in development, the diffusion of new drugs, generic drugs, health care reform, drug safety concerns, and comparative effectiveness research. The increasing availability of important generic drugs continues to moderate growth in drug expenditures. Health care reform initiatives, including the potential for biosimilars legislation, will influence drug expenditures in all settings. From 2007 to 2008, total U.S. drug expenditures increased by 1.8%, with total spending rising from $279.6 billion to $284.7 billion. Growth in drug expenditures in clinics declined to the lowest level in a decade, a 1.0% increase from 2007 to 2008. Hospital drug expenditures increased at a moderate rate of only 2.1% from 2007 to 2008; through the first nine months of 2009, hospital drug expenditures increased by 3.0% compared with the same period in 2008. CONCLUSION In 2010, we project a 3-5% increase in drug expenditures in outpatient settings, a 6-8% increase in expenditures for clinic-administered drugs, and a 2-4% increase in hospital drug expenditures.

[1]  Kosa Sudhorm,et al.  Pandemic (H1N1) 2009 , 2009 .

[2]  J. Hodgson WHO guidelines presage US biosimilars legislation? , 2009, Nature Biotechnology.

[3]  M. Wadman When the party's over , 2007, Nature.

[4]  R. Steinbrook Health care and the American Recovery and Reinvestment Act. , 2009, The New England journal of medicine.

[5]  "Me-too" products--friend or foe? , 2004, The New England journal of medicine.

[6]  Nilay D Shah,et al.  Projecting future drug expenditures--2006. , 2006, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[7]  E. Rogers,et al.  Diffusion of Innovations , 1964 .

[8]  N. Shah,et al.  Projecting future drug expenditures--2004. , 2004, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[9]  D. Cutler The demise of the blockbuster? , 2007, The New England journal of medicine.

[10]  Nilay D Shah,et al.  Projecting future drug expenditures--2005. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[11]  Micah B. Hartman,et al.  Health spending growth at a historic low in 2008. , 2010, Health affairs.

[12]  N. Shah,et al.  Projecting future drug expenditures--2009. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[13]  Bruce D Cheson,et al.  Bendamustine: rebirth of an old drug. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A Simon Pickard,et al.  Comparative effectiveness research: Relevance and applications to pharmacy. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[15]  J. Gabel,et al.  Health benefits in 2008: premiums moderately higher, while enrollment in consumer-directed plans rises in small firms. , 2008, Health affairs.

[16]  Alvin I Mushlin,et al.  Health care reform and the need for comparative-effectiveness research. , 2010, The New England journal of medicine.

[17]  Thomas J. Smith,et al.  American Society of Clinical Oncology guidance statement: the cost of cancer care. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Bethan Hughes,et al.  2008 FDA drug approvals , 2009, Nature Reviews Drug Discovery.